(A) In vivo tumorigenicity assay with limited dilution; HT29 cells pretreated with control CM or LPEC CM.
(B) In vivo tumorigenicity assay with limited dilution combined with serial transplantation using freshly isolated xhCRC cells pretreated with control CM or LPEC CM.
(C/D) Hepatic metastatic incidence and burden of xhCRC cells pre-treated with control CM or LPEC CM in a splenic injection model (*p<0.05, mean ± SEM).
(E) Representative immunofluorescent staining of CD133 and CD31 in human primary CRC surgical specimens (left panel), and human CRC liver metastases (right panel). The highlighted region in the upper panel is enlarged in the lower panel.
See also Figure S2.